Machine signal
Active cluster sell — 3 distinct insiders, $7.2M, window ends Aug 13, 2026.
Figures computed from official regulatory filings — .
Analysttarget 22.71 USD (+12%) · consensus 4.57/5 · 7 buy · 0 hold · 0 sell
Ownershipinsiders 52.1% · institutions 48.6% · short 4.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Amneal Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
30 buys56 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BUCHI J KEVINtrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BUCHI J KEVINtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BUCHI J KEVINtrack record | Exercise | $295.4K | SEC |
| BOYER ANDREW S | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BOYER ANDREW S | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kiely John | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kiely John | Sell | $882K | Unusual size | SEC |
| Daly Jason B. | Sell | $3.7M | Unusual size | SEC |
| Daly Jason B. | Sell | $117.1K | SEC |
| BUCHI J KEVINtrack record | Exercise | $2.9M | Unusual size | SEC |
| Shah Nikita | Sell | $2.6M | Unusual size | SEC |
| Patel Chirag K.track record | Award | n/a (No price was disclosed in the filing) | SEC |
| Patel Tushar Bhikhubhai | Award | n/a (No price was disclosed in the filing) | SEC |
| Patel Chintutrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Patel Gautam | Award | n/a (No price was disclosed in the filing) | SEC |
| Autor Deborah M. | Sell | $450.6K | Unusual size | SEC |
| Patel Gautam | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Patel Gautam | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Yanai Shlomo | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BUCHI J KEVINtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Autor Deborah M. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Autor Deborah M. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kiely John | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Autor Deborah M. | Exercise | n/a (No price was disclosed in the filing) | SEC |
| George Jeffrey P. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |